RELIEF THERAPEUTICS Holding SA (“Relief”, “the Company”) announces today that a capital increase pursuant to a draw down was carried out in the context of the Share Subscription Facility in place with the Company main shareholder GEM since December 2015. The share capital of the Company has been increased by CHF 249’988 corresponding to 24’998’800 shares with a par value of CHF 0.01. The new share capital of the Company is now CHF 21’139’192.72 constituted by 2’113’919’272 shares with a par value of CHF 0.01. This has been registered at the Geneva Commercial Register and the Articles of Association of the Company have been adapted accordingly.

About Relief Therapeutics Holding SA

RELIEF THERAPEUTICS Holding AG is a clinical-stage biotechnology company with a portfolio of drug candidates derived from natural human origins. Its two first candidates are Aviptadil for the treatment of sarcoidosis (to enter Phase III) and low dose interleukin-6 (Atexakin alfa) for the treatment of peripheral neuropathy (to enter Phase II). Aviptadil development in sarcoidosis addresses the orphan disease market, in which European regulators have indicated that a single pivotal Phase III trial would be sufficient to support approval. Atexakin alfa is the subject of an exclusive worldwide development and commercialization agreement with Merck KGaA, The current priority indication for Atexakin is to alleviate peripheral diabetic neuropathy, a market that is estimated to reach $4.1 billion in 2019 (source Datamonitor).

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and is headquartered in Geneva, Switzerland.

For further information, please visit the Relief website at www.relieftherapeutics.com  or contact investor relations. 

Relief Therapeutics Holding SA

Investor Relations: This email address is being protected from spambots. You need JavaScript enabled to view it.